Eli Lilly and Company (NYSE:LLY) has been given a $73.00 price target by investment analysts at BMO Capital Markets in a research note issued to investors on Monday. The brokerage currently has a “sell” rating on the stock. BMO Capital Markets’ price target suggests a potential downside of 15.18% from the stock’s previous close.

LLY has been the topic of a number of other research reports. Piper Jaffray Companies reiterated a “buy” rating and set a $103.00 target price on shares of Eli Lilly and in a research note on Thursday, August 31st. Credit Suisse Group lowered Eli Lilly and from an “outperform” rating to a “neutral” rating and increased their target price for the stock from $84.23 to $88.00 in a research note on Tuesday, October 10th. Zacks Investment Research upgraded Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 target price on the stock in a research note on Monday, July 17th. Jefferies Group LLC reiterated a “buy” rating and set a $89.00 target price (down previously from $94.00) on shares of Eli Lilly and in a research note on Thursday, August 24th. Finally, Cowen and Company reiterated a “buy” rating and set a $95.00 target price on shares of Eli Lilly and in a research note on Wednesday, October 4th. Three analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have given a buy rating to the stock. Eli Lilly and has a consensus rating of “Hold” and an average price target of $88.97.

Shares of Eli Lilly and (NYSE LLY) opened at 86.06 on Monday. The stock’s 50 day moving average price is $83.56 and its 200 day moving average price is $82.19. Eli Lilly and has a one year low of $64.18 and a one year high of $89.09. The firm has a market cap of $90.79 billion, a price-to-earnings ratio of 37.24 and a beta of 0.34.

Eli Lilly and (NYSE:LLY) last announced its earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.05 by $0.06. The company had revenue of $5.82 billion for the quarter, compared to analyst estimates of $5.60 billion. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The firm’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same quarter last year, the company earned $0.86 earnings per share. On average, equities analysts anticipate that Eli Lilly and will post $4.16 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/10/18/eli-lilly-and-company-lly-pt-set-at-73-00-by-bmo-capital-markets.html.

In other news, major shareholder Lilly Endowment Inc sold 220,000 shares of the stock in a transaction on Monday, July 31st. The stock was sold at an average price of $83.09, for a total value of $18,279,800.00. Following the completion of the transaction, the insider now directly owns 124,049,283 shares in the company, valued at approximately $10,307,254,924.47. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold a total of 990,000 shares of company stock valued at $82,949,650 over the last quarter. 0.20% of the stock is owned by corporate insiders.

Several institutional investors and hedge funds have recently made changes to their positions in LLY. Waldron LP lifted its stake in shares of Eli Lilly and by 46.7% in the 1st quarter. Waldron LP now owns 4,948 shares of the company’s stock valued at $415,000 after acquiring an additional 1,574 shares during the last quarter. Davis R M Inc. lifted its stake in shares of Eli Lilly and by 3.1% in the 1st quarter. Davis R M Inc. now owns 13,827 shares of the company’s stock valued at $1,163,000 after acquiring an additional 410 shares during the last quarter. Pinnacle Financial Partners Inc. lifted its stake in shares of Eli Lilly and by 10.7% in the 1st quarter. Pinnacle Financial Partners Inc. now owns 34,952 shares of the company’s stock valued at $2,940,000 after acquiring an additional 3,378 shares during the last quarter. Solaris Asset Management LLC lifted its stake in shares of Eli Lilly and by 165.0% in the 1st quarter. Solaris Asset Management LLC now owns 2,650 shares of the company’s stock valued at $223,000 after acquiring an additional 1,650 shares during the last quarter. Finally, Strategic Advisors LLC bought a new position in shares of Eli Lilly and in the 1st quarter valued at $396,000. Institutional investors own 75.53% of the company’s stock.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Analyst Recommendations for Eli Lilly and (NYSE:LLY)

Receive News & Stock Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related stocks with our FREE daily email newsletter.